Company / Return on Equity (ROE)
Actinium Pharmaceuticals, Inc. Return on Equity (ROE) History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-432.6%
FY2025
5-year range
-432.6% / -30.2%
FY2021-FY2025
Trend
-222.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Actinium Pharmaceuticals, Inc. reports negative total equity of -432.6% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-432.6% in FY2025 with a 3-year CAGR of -398.9%.
Declined from -49.7% to -432.6% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -398.9pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- Actinium Pharmaceuticals, Inc.'s return on equity (roe) has declined for 4 consecutive years.
- In FY2025, return on equity (roe) decreased 222.3% year-over-year.
- Peak return on equity (roe) was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -432.6% | -222.3% |
| FY2024 | -134.2% | -170.2% |
| FY2023 | -49.7% | -47.4% |
| FY2022 | -33.7% | -11.5% |
| FY2021 | -30.2% | +91.3% |
| FY2011 | -347.3% | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026